Medesthetics

JUL-AUG 2018

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link: https://medesthetics.epubxp.com/i/995786

Contents of this Issue

Navigation

Page 23 of 68

Retinol 0.5 Retinol 1.0 Tretinoin Cream 0.025% Tretinoin Cream 0.1% Retivance ® Skin Rejuvenating Complex Tretinoin Cream 0.05% Tretinoin Gel 0.05% A Comprehensive Portfolio of Obagi Retinoids INDICATION Tretinoin Gel 0.05% and Tretinoin Cream (0.1%, 0.05% and 0.025%) are indicated for the topical treatment of acne vulgaris. IMPORTANT SAFETY INFORMATION • If a reaction suggesting sensitivity or chemical irritation occurs, discontinue use of Tretinoin. • The skin of some patients may become dry, red or exfoliated while using Tretinoin and patients may need to temporarily reduce the amount or frequency of application, or discontinue use temporarily or altogether. • Tretinoin should not be used on sunburned skin due to potential for severe irritation, and utmost caution must be used if it is prescribed for patients with eczema. Use of effective broad-spectrum sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. • Caution should be exercised when using Tretinoin with products that have a strong drying effect, particularly those containing benzoyl peroxide, sulfur, resorcinol or salicylic acid. • Tretinoin Gel should be used with caution in patients allergic to fish due to potential for allergic reactions to fish protein; patients who develop pruritus or urticaria should contact their healthcare providers. • The safety and efficacy of Tretinoin have not been established in the treatment of patients younger than 10 years of age (gel) and 12 years of age (cream). • The most common adverse reactions are dry skin, peeling/scaling/flaking skin, skin burning sensation and erythema. In some subjects the skin-related adverse reactions persisted throughout the treatment period. ®/TM are trademarks of Obagi Cosmeceuticals LLC. RETIVANCE is a trademark of Nextcell Medical Company used under license. All other product/brand names are trademarks of the respective owners. Distributed by Obagi Cosmeceuticals LLC. ©2018 Obagi Cosmeceuticals LLC. All rights reserved. OBG.0072.USA.18.r0 Whatever your patient's retinoid needs, there's an Obagi option for them. For more information about Obagi ® products, visit www.obagi.com.

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - JUL-AUG 2018